BMO Capital Markets has recently initiated Taysha Gene Therapies Inc (TSHA) stock to Outperform rating, as announced on June 27, 2024, according to Finviz. Earlier, on April 9, 2024, Piper Sandler had initiated the stock to Overweight, setting a price target of $9. Jefferies also reduced Hold rating with a price target of $1.50. Additionally, Morgan Stanley reduced their rating on January 27, 2023, with a target price of $3. Goldman analysts, in their report published on November 9, 2022, also reduced Neutral rating and set a price target of $3 for Taysha Gene Therapies Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Sponsored
Taysha Gene Therapies Inc (TSHA) Stock Trading Recap
On Monday, Taysha Gene Therapies Inc (TSHA) stock saw a decline, ending the day at $2.01 which represents a decrease of $-0.06 or -2.90% from the prior close of $2.07. The stock opened at $2.07 and touched a low of $1.98 during the day, reaching a high of $2.11. The volume of shares traded was 3.09 million exceeding the average volume of 1.92 million.
TSHA Stock Performance and Moving Averages
In recent trading, Taysha Gene Therapies Inc (TSHA) stock price has shown some volatility, fluctuating -0.99% over the last five trades and -6.51% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by -29.23%, and it has plunged by -11.06% in the previous three months. Currently, TSHA is trading at -6.53%, -7.60%, and -14.47% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, TSHA, a Healthcare sector stock, is trading -53.47% below its 52-week high but remains 58.27% above its 52-week low. The Average True Range (ATR) (14 days) of 0.13 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Taysha Gene Therapies Inc’s Profitability and Valuation Ratios
Taysha Gene Therapies Inc’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of -598.62% and a profit margin of -888.18%, with a gross margin of -29.23%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Taysha Gene Therapies Inc’s market capitalization stands at $411.93 million. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. Additionally, the Price-to-Sales Ratio is 32.01, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 3.72, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 22.67% of Taysha Gene Therapies Inc (TSHA)’s shares, while financial institutions hold 72.80%.
